AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 25 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - The proposed use of Lactococcus lactis as a mucosal adjuvant cannot be supported in the case of Helicobacter pylori vaccination, say researchers working in England.
Their report, published in Vaccine, described research with L. lactis as an adjuvant for H. pylori urease subunit B (UreB) in mice.
"Constitutive expression of UreB by a pTREX1 vector resulted in the intracellular accumulation of UreB to approximately 6.25% of soluble cellular protein. Five different oral regimens were used to vaccinate C57BL/6 mice and the immune response measured," reported M.H. Lee and colleagues.
Only one regimen - four weekly doses of 10(10) bacteria, followed after four weeks by three successive daily doses - stimulated a systemic antibody response to UreB, but it could not be repeated successfully, said Lee and coworkers.
The other three protocols failed to elicit significant anti-UreB serum antibody responses, and vaccinated mice were not protected against later challenge with H. pylori strain SS1 ("Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice," Vaccine, July 2001;19(28-29):3927-3935).
...Source: HighBeam Research, Lactococcus Lactis Fails To Deliver Protection.(Brief Article)